Neurocrine Biosciences, Inc. will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief Executive Officer Kyle Gano and Chief Medical Officer ...

NEW YORK CITY, NY / ACCESS Newswire / March 16, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds ...

NEW YORK CITY, NY / ACCESS Newswire / March 15, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds ...

GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

Discover GSK's impressive stock surge, boosted by strong earnings, a share buyback program, and a focus on specialty medicines.

Hesham Abdullah, GSK's Senior Vice President, Global Head Oncology R&D, stated, "This acquisition adds to GSK's growing pipeline of targeted therapeutics for cancers originating in the ...

GSK has had another setback in its oncology business, after the FDA asked it to restrict use of its PARP inhibitor Zejula in ovarian, fallopian tube, or primary peritoneal cancer to patients with ...

having been knocked back by US lawsuits over the alleged cancer risks of discontinued heartburn drug Zantac. Even after GSK reached a $2.2bn settlement in October, resolving the majority of cases ...

The post hailed “promising results” from a trial of GSK’s PARP inhibitor niraparib in brain cancer patients; the drug, sold as Zejula, is currently approved as a maintenance treatment for ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Hesham Abdullah, GSK's Senior Vice President, Global Head Oncology R&D, stated, "This acquisition adds to GSK's growing pipeline of targeted therapeutics for cancers originating in the ...